Please provide your email address to receive an email when new articles are posted on . The subcutaneous pembrolizumab combination was approved for adults and ...
The US FDA has approved pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex, Merck), a subcutaneous version of the intravenous formulation of Keytruda, for adults and children aged 12 years ...
KEYTRUDA QLEX is the first and only subcutaneously administered immune checkpoint inhibitor that can be given by a health care provider in as little as one minute RAHWAY, N.J.--(BUSINESS WIRE)-- Merck ...
Subcutaneous nivolumab and hyaluronidase-nvhy is FDA-approved for adult solid tumors, offering a new administration route for PD-1 inhibitors. The phase 3 CheckMate-67T trial confirmed noninferiority ...
Pucotenlimab in high microsatellite instability/mismatch repair–defificient (MSI-H/ dMMR) solid tumors: Results update from a multicenter, phase II, open-label study. This is an ASCO Meeting Abstract ...
FDA approved pembrolizumab and berahyaluronidase alfa-pmph for patients aged 12 and older with solid tumors. Study MK-3475A-D77 showed a 45% ORR in subcutaneous administration for treatment-naïve ...
Dr. Balazs Halmos discusses the significance of the FDA approval of the subcutaneous injection formulation of Opdivo for patients with solid tumors. The Food and Drug Administration (FDA) approval of ...
Subcutaneous Immunotherapies in Solid Tumors: Are We Truly Expanding Access and Efficiency? The following represents disclosure information provided by authors of this manuscript. All relationships ...
Keytruda Qlex, a subcutaneous formulation, is FDA-approved for solid tumors in patients 12 and older, offering an alternative to intravenous administration. Study MK-3475A-D77 showed comparable ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results